Laekna, a clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application of LAE102 antibody to initiate clinical development.
